Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 49, 5816-5822, November 1, 1989]
© 1989 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kawabata, T. T.
Right arrow Articles by White, K. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kawabata, T. T.
Right arrow Articles by White, K. L., Jr.

Benzo(a)pyrene Metabolism by Murine Spleen Microsomes1

Thomas T. Kawabata2 and Kimber L. White, Jr.

Departments of Pharmacology and Toxicology and Biostatistics, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298

The immunosuppressive actions of benzo(a)pyrene have been proposed to be mediated by reactive metabolites rather than the parent compound. Reactive metabolites which suppress splenic humoral immune responses are thought to be generated within the spleen rather than in distant tissues. Although the spleen has been shown to be capable of metabolizing benzo(a)pyrene, the relative amounts and types of metabolites generated have not been determined. In this study, high-pressure liquid chromatography was used to separate benzo(a)pyrene metabolites generated by splenic microsomes. The major metabolites generated by the splenic microsomal preparations of untreated female B6C3F1 mice were found to be the 9,10- and 7,8-dihydrodiols and 9-, 7-, and 3-hydroxy benzo(a)pyrene. The 1,3-, 3,6-, and 6,12-diones and 4,5-dihydrodiol constituted only a small fraction of the metabolites generated. The generation of all metabolites were inhibited by {alpha}-naphthoflavone and antiserum to NADPH-cytochrome P-450 reductase, whereas SKF 525-A had only a minimal effect. Dihydrodiol production was completely inhibited by the epoxide hydrolase inhibitor, trichloropropylene oxide. Benzo(a)pyrene pretreatment of mice produced a dramatic increase in the amount of metabolites formed; however, the pattern of metabolites remained similar to that generated by splenic microsomes of untreated mice. The role of prostaglandin synthetase in generating these metabolites was also examined. The addition of arachidonic acid in place of NADPH resulted in the formation of only quinones. Dihydrodiols and phenols were undetectable. The results of this study indicate that splenocytes may be capable of generating the 7,8-dihydrodiol, the precursor to the highly reactive 7,8-dihydrodiol-9,10-epoxide. Furthermore, the addition of the 7,8-dihydrodiol-9,10-epoxide to splenocyte cultures resulted in a decreased in vitro antibody forming cell response to sheep red blood cells. Thus, benzo(a)pyrene-induced immunosuppression may be mediated by the dihydrodiol-epoxide generated within the spleen. Since benzo(a)pyrene exposure was found to increase its own metabolism, immunosuppression produced by the administration of benzo(a)pyrene over several days may be the result of an increased production of immunosuppressive metabolites. The pattern of metabolites generated and the effects of the two types of cytochrome P-450 inhibitors suggests that the major isozyme of cytochrome P-450 that mediates the metabolism of benzo(a)pyrene within the spleen of untreated mice may be similar to the isozyme induced in the liver upon pretreatment with polycyclic aromatic hydrocarbons.

1 Research supported in part by USPHS Grant ES03434, NIEHS Contract ES55094, and a Virginia Commonwealth University Grant in Aid.

2 To whom all reprint requests should be addressed, at Medical College of Virginia, Virginia Commonwealth University, Department of Pharmacology and Toxicology, Box 613- MCV Station, Richmond, VA 23298-0613.

Received 1/31/89. Revised 4/17/89. Revised 8/ 1/89. Accepted 8/ 7/89.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1989 by the American Association for Cancer Research.